Iktos
Marion Laguette has a diverse work experience spanning various industries and roles. In 2012, they interned at Gendarmerie Nationale as a Stagiaire adjoint au Commandant de Compagnie. In 2014, they interned at Michelin in the Environment and prevention department. In 2015, they worked as a Research intern at Institut Pasteur in the "Immune Regulation and Vaccinology" laboratory, studying the role of plasmacytoid dendritic cells in tumor development. In 2016, they interned at Imperial College London in the "Metabolomics" laboratory, researching the adaptation of S. aureus to the lung of cystic fibrosis patients. From 2016 to 2021, Marion worked at CEPTON Strategies, starting as a Consultant and progressing to Senior Consultant and Project Manager. Currently, they are working at Iktos as the Associate Director - Strategic Planning and Corporate Development, and their role will transition to Director - Strategic Planning, Corporate Development, and Operations in February 2023. Marion's work experience showcases their expertise in project management, strategic planning, research, and corporate development.
Marion Laguette attended École Polytechnique from 2012 to 2016, where they studied Engineering and Biotechnology. In 2015, they also pursued an MSc in Applied Biosciences and Biotechnology at Imperial College London, completing their studies there in 2016.
This person is not in any teams
This person is not in any offices
Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existingdata, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as a professional services and as a SaaS software platform. Iktos offers Makya™, ligand and structure-based de novo drug design platform for multi-parametric optimisation (MPO) of lead compounds in line with Target Candidate Profile (TCP). Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis.